More than one in five breast cancer patients will have their disease recur, according to Macmillan Cancer Support research presented at National Cancer Intelligence Network conference in Birmingham, England, in June.

When the Congressional Budget Office (CBO) released its analysis of the Supreme Courts ruling in the Patient Protection and Affordable Care Act (PPACA), many reports focused on the cost savings: $84 billion. Few pointed out the nuances within the 21-page document.

The marketing authorization from the European Commission has granted Boehringer Ingelheim and Eli Lilly regulatory approval of Jentadueto (linagliptin/metformin hydrochloride) tablets, a medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta tablets, marketed under the trade name Trajenta in Europe) and metformin in a single tablet taken twice daily.

From the mid-1990s to mid-2000s, advanced imaging grew at a robust clip, surpassing 6 percent per year, and exceeding 20 percent annually in some market segments. Growth of advanced imaging among Medicare beneficiaries started to slow in 2006, and research suggests the slowdown extended to the non-Medicare insured. The expansion of prior authorization, increased cost sharing and other policies fueled the slowdown, according to a study published online July 25 in Health Affairs. The American College of Radiology characterized the list of factors cited for the decline as incomplete and emphasized that the drop in imaging use is not without adverse consequences.

Another study has shown an association between florbetapir PET scans of amyloid plaques and brain amyloid pathology, as autopsies revealed very high sensitivity and specificity for the detection of beta-amyloid plaques using the imaging technique, according to research published in the August issue of The Lancet Neurology.

MR/PET systems offer specific advantages compared with PET/CT and are expected to carve a role in oncologic imaging as well as cardiovascular and neurologic diseases, according to a review article published in the August issue of American Journal of Roentgenology.

The FDA has granted 510(k) clearance to the Corindus Vascular Robotics' CorPath 200 system to be used during PCI procedures.

Rolling Oaks Radiology, a division of RadNet, has installed GE Healthcare's SenoBright contrast-enhanced spectral mammography at its Oxnard, Calif. location.